Skip to main content
  • Publisher Correction
  • Open access
  • Published:

Publisher Correction: Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort

The Original Article was published on 17 May 2022

Publisher Correction: BMC Psychiatry 22, 342 (2022)

https://doi.org/10.1186/s12888-022-03983-3

Following the publication of the original article [1], the authors identified errors in the figure captions.

Fig. 1 aDefined using the International Diabetes Federation definition; bBMI by 10 kg.m-2. c Estimated risk of death from cardiovascular diseases within 10 years using the Systematic Coronary Risk Estimation. Models were adjusted for age, sex, smoking status, and psychotropic medication (classified by the risk of weight gain), except the model for CVD which was adjusted only for psychotropic medication. 1 Models fitted with random effect at observation level. 2 Models fitted with random effect at patient level. ***: p-value < 0.001; **: p-value ≤ 0.01; *: p-value ≤ 0.05. Correction for multiple testing was applied using false discovery rate. Abbreviations: BMI body mass index, CVD cardiovascular diseases, HDL high-density lipoprotein, MetS metabolic syndrome, N number

figure a

Fig. 2 Model for FPG was adjusted for time, age, sex, smoking status and psychotropic medication. Model for TG was adjusted for time, age, interaction between age and insomnia disorders, sex, smoking status, setting of care (in/outpatient) and psychotropic medication. Model for HDL-C was adjusted for time, age, interaction between age and insomnia disorders, smoking status and psychotropic medication. Model for LDL-C was adjusted for time, age, interaction between age and insomnia disorders, sex and smoking status. Model for Total-C was adjusted for time, age, sex, interaction between age and insomnia disorders, sex, smoking status and psychotropic medication. Models for 10-year CVD risks (FRS and SCORE) were adjusted for time and psychotropic medication. ***:p-value < 0.001; **p-value < 0.01; *:p-value ≤ 0.05. Correction for multiple testing was applied using false discovery rate. Abbreviations: FPG fasting plasma glucose, FRS Framingham Risk Score, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, N number, SCORE  Systematic Coronary Risk Estimation, Total-C total cholesterol, TG triglycerides

figure b

Fig. 3 Models for BMI and waist circumference were adjusted for time, age, interaction between age and insomnia disorders, sex, smoking status, and psychotropic medication. Model for diastolic blood pressure was adjusted for time, age, interaction between age and insomnia disorders, sex and psychotropic medication. ***:p-value < 0.001; **: p-value < 0.01;*:p-value ≤ 0.05. Correction for multiple testing was applied using false discovery rate. Abbreviations: BMI body mass index, N number

figure c

The original article [1] has been corrected.

Reference

  1. Laaboub N, et al. Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort. BMC Psychiatry. 2022;22:342. https://doi.org/10.1186/s12888-022-03983-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chin B. Eap.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laaboub, N., Dubath, C., Ranjbar, S. et al. Publisher Correction: Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort. BMC Psychiatry 22, 457 (2022). https://doi.org/10.1186/s12888-022-04040-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12888-022-04040-9